DEXCOM INC 8-K

What Happened
DexCom, Inc. announced the results of its May 27, 2026 Annual Meeting of Stockholders. At the April 1, 2026 record date there were 385,872,977 shares outstanding; 336,525,352 shares were present or represented by proxy. Stockholders elected all 12 director nominees to terms ending at the 2027 annual meeting, ratified Deloitte & Touche LLP as the company’s independent auditor for FY2026, and approved the advisory vote on named executive officer compensation (say‑on‑pay).

Key Details

• Shares outstanding (record date): 385,872,977; shares present/represented: 336,525,352 (quorum).
• Directors elected (12): Steven Altman; Dr. Euan Ashley; Nicholas Augustinos; Richard Collins; Rimma Driscoll; Mark Foletta; Renée Galá; Bridgette Heller; Jacob Leach; Kyle Malady; Rick Osterloh; Kevin Sayer. Nicholas Augustinos received the highest opposition (47,957,634 votes against, ≈15.3% of votes cast for his election). Broker non‑votes for director and say‑on‑pay matters: 22,107,994.
• Auditor ratification: Deloitte & Touche LLP ratified — Votes for: 336,046,596; against: 373,544; abstentions: 105,212.
• Say‑on‑pay (non‑binding): Approved — Votes for: 277,111,475; against: 36,664,959 (≈11.7% of votes cast); abstentions: 640,924; broker non‑votes: 22,107,994.

Why It Matters
The voting results confirm board continuity with all 12 nominees re‑elected and formalize Deloitte as the independent auditor for the coming year—both items that affect governance and financial oversight. The say‑on‑pay approval is advisory (non‑binding) but the size of the opposition (~36.7M votes against) and the elevated opposition to one director (Nicholas Augustinos) are signals of shareholder sentiment that the company’s board and management may monitor going forward.